approach to the management of patients with cirrhosis during transplant selection [2] includes the evaluation of the infectious risk, aiming to prevent or reduce both the risk of infection-related drop out from the waiting list and the negative impact on the outcome after LT.
Patients with cirrhosis often develop sepsis as a result of the dysfunction of the defensive mechanisms against bacterial, viral or fungal infections [3] . The overall mortality of infected patients is reported to be as high as 38% (odds ratio for death of infected vs. non-infected patients of 3.75) [4] . Spontaneous bacterial peritonitis (SBP) represents one of the most common infectious complications reported in patients with cirrhosis while waiting for LT.
Liver transplantation is a major, lengthy and complex surgical procedure performed on severely ill patients. Therefore identification, control, decolonization, and eradication of either bacterial, viral, fungal, or parasitic infections is paramount. A microbial burden that may be kept under control by the host's immune system before transplant may acquire notable relevance after the combination of major surgery and immunosuppression.
Risk of post-transplantation infections
Bacterial infections, especially those involving gram-negative bacteria, represent a major complication in liver transplant recipients, the frequency ranging between 20% and 80% of cases, and they contribute to longer hospital stays and increased hospital costs [5] . Three-fourths of bacterial infectious episodes occur in the first month after transplantation [6] . Most of these infections are endogenous and arise from aerobic gram-negative bacteria (GNB) and yeasts that have colonized the oropharynx, stomach and bowel [7] .
The role of selective digestive tract decontamination (SDD) with antibiotics in the prevention of bacterial infections in liver transplant recipients is still a matter of debate [8] . A recent study from Spain did not confirm that fluoroquinolones administered from the time of transplantation have any protective effect against the development of early bacterial infections after liver transplantation [6] .
Liver transplant recipients may be at risk for developing mycobacterial infections due to latent tuberculosis (TB). However, once the diagnosis is made and the specific treatment is adopted, patient survival is similar to that of liver transplant recipients without latent TB [9] .
Invasive fungal infections (IFI) and Cytomegalovirus (CMV) infection are important causes of morbidity and mortality in liver transplant recipients. A significant reduction in both fungal and CMV infections was demonstrated by adopting prophylactic regimens [10] [11] [12] .
Aims
The goal of this document is to provide clinical guidelines for the appropriate management of infections in the setting of liver transplantation.
Methods
The promoter of these ''Consensus Guidelines'' was the Italian association for the Study of the Liver (AISF), which identified a scientific board of Experts in charge of the document preparation. The Consensus was endorsed by the Italian society for Infectious and Tropical Diseases (SIMIT). The scientific board defined the methodology utilized as well as the goals, and acted as developer and reviewer. The methodology chosen involved the following steps:
(a) The promoters and the scientific board selected the main topics of interest: (1) Epidemiology of infections in the transplant setting, (2) Pre-LT infectious work up, (3) Management of infections in the post-LT, (4) Treatment of infections in liver transplantation. (b) For each topic, a working party was identified by both the promoters and the scientific board, and was composed of a group of at least four experts guided by a chairman. The chairman, together with the promoters and the scientific board, selected the relevant clinical questions regarding both clinical practice and controversial areas. The questions were circulated within the working groups to refine the topics and to avoid duplications. The members of the working parties were identified on the basis of competence, role, expertise and publications/research in the field of infections, end stage liver disease and liver transplantation. (c) The working groups independently carried out a systematic literature search and review, using Medline/ PubMed to support definitions and statements. Each recommendation was graded according to the Centre for Disease Control's (CDC grading system, Supplementary Table 1 ) (d) The working groups elaborated the proposed statements, graded according to the selected grading system. They prepared the statements together with the presentation of the literature review for each topic during video-conferences, group meetings, and correspondence before the Consensus Conference (e) The jury members were by no means involved in the selection, preparation, and discussion of the topics and statements prior to the Consensus Conference. (f) All the promoters, members of the scientific board, working groups, and jury invited to participate to the Consensus Conference were asked to declare any potential conflict of interests.
A Consensus Meeting was held in Bergamo in 2012. The consensus group consisted of a total of 124 participants (including promoters, scientific board, working groups, jury). The jury was selected among infectious disease specialists, hepatologists, microbiologists, intensive care physicians, surgeons, epidemiologists, patient representatives and ethicists. During the first sessions, the chairman of each group presented the selected topics and the proposed statements for each question. A general discussion was held in order to refine the statements and identify the possible adjustments. At the end of the general session, each group met independently to re-elaborate the final statements to be presented in the final voting session according to the suggestions received. The final general session consisted in the presentation of every single statement by the chairman of each working group, followed by an electronic vote from the jury. The agreement scale consisted of 2 levels of agreement (Agree, Disagree). The results of jury voting are available online as Supplementary data.
Vaccination and liver transplantation

Pretransplantation
Despite emerging evidence that vaccinations are safe and effective among immunosuppressed patients, most vaccines are still underutilized in these patients. The efficacy, safety, and protocols of several vaccines in this patient population are poorly understood. Timing of vaccination appears to be critical because response to vaccinations is decreased in patients with end-stage organ disease and within the first 6 months after transplantation. In addition, liver transplant candidates might often wait for an unpredictable length of time before a suitable donor is available, and during this interval, all recommended vaccinations as well as boosts should be given. Although vaccination responses in some patients awaiting transplantation are suboptimal, antibody responses are usually even more attenuated when vaccines are administered after transplantation [13] [14] [15] . For these reasons, primary immunizations should be given before transplantation, and as early as possible during the course of disease. The vaccination strategy should include vaccination of household contacts and health care workers at transplant centres, unless contraindicated. In the transplant population, however, no conclusive data are available on the use of immune-adjuvants and on the screening for protective titres. Nevertheless, most vaccines appear to be safe in solidorgan transplantation recipients, but live vaccines should be avoided until further studies are available. The risk of rejection following vaccinations appears to date minimal.
The following are the indicated vaccinations for paediatric transplant candidates [16] : Inactivated: Influenza, Hepatitis A and B, Pertussis, Diphtheria, Tetanus, Polio (inactivated), Haemophilus influenzae, Streptococcus pneumoniae (conjugated or polysaccharide vaccine), and Neisseria meningitidis. Live attenuated: Varicella, Measles, Mumps, and Rubella. Rabies vaccine is not routinely administered, and is recommended for exposures, or potential exposures due to vocation or avocation. Smallpox and anthrax vaccinations are not routinely recommended in the pretransplant setting.
In adult liver transplantation candidates, the following vaccinations are indicated [16] : Inactivated: Influenza, Hepatitis A and B, Tetanus, Polio (inactivated), Streptococcus pneumoniae (conjugated or polysaccharide vaccine) and Varicella (live attenuated). Other vaccinations are indicated in special circumstances: Neisseria meningitidis is recommended in members of the military, travellers to high risk areas, in cases of properdin deficiency, terminal complement component deficiency, and in patients with functional or anatomic asplenia.
Specific contraindications exist for other vaccines, including the oral polio vaccine, Calmette-Guerin's bacillus, and Smallpox.
Post-transplantation
Current data seem to support the assumption that solid-organ recipients will benefit from consistent immunization practices; however, further studies are recommended to improve established protocols in this patient population [17] .
In general, the following vaccinations are recommended for paediatric transplant recipients [16] Comment: A systematic review of 7 studies estimated that, compared with the general population, liver transplant recipients have a 18-fold increase in the prevalence of active Mycobacterium tuberculosis infection and a 4-fold increase in the case-fatality rate [18] (Supplementary Table 2) .
IGRA (Quantiferon TB Gold test or T-spot TB) must be performed, together with PPD, due to the high rate of false negative PPD test in immunodeficient patients [19, 20] . Comment: In case of isoniazid-resistance or intolerance, rifampicin (10 mg/kg/d, max 600 mg/d, for 4 months) or ethambutol + levofloxacin according to ID consult can be indicated. Except for isoniazid-resistance, no different therapeutic regimens can be recommended, as no better efficacy has been documented and due to the major risk of both toxicity and drug-interactions. Comment: A low efficacy of vaccination has been documented and TB vaccination is not recommended in liver transplant candidates. Although it would be optimal to treat TB infection prior to liver transplantation, it is challenging due to potential isoniazid hepatotoxicity.
Mortality rate is higher in liver transplant recipients who developed active TB infection within 5 months post-transplant vs. patients who developed active TB infection after 5 months (36% vs. 17%, p = 0.04) [21] [22] [23] . Comment: IFIs and viral infections are important causes of morbidity and mortality in solid organ transplant recipients [10, 24] . Comment: SBP is mainly caused by Enterobacteriaceae. Empirical therapy is based on 3rd generation cephalosporins. Cefotaxime 2 g tid for 5 days is as effective as higher dosages and longer treatments but it is not superior to other cephalosporins. Orally or intravenously administered quinolones have shown the same efficacy as cephalosporins, even though in studies characterized by a low statistical power. SBP treatment with quinolones should be avoided if previous prophylaxis with norfloxacin had been instituted. Aminoglycosides should be avoided for risk of renal toxicity. Patients with bacterial infections other than SBP should be treated according to specific guidelines for single infections (e.g., pneumonia, Skin and Soft Tissue Infections (SSTI), Urinary Tract Infection (UTI) etc. and local epidemiology of bacterial resistance) [25] . Comment: The diagnostic work-up and therapy (empirical or targeted), should be performed by a multidisciplinary team, including an expert in transplant infectious diseases.
Atypical presentations, poor outcomes and nosocomial antimicrobial-resistant pathogens must be considered [28] . Empiric anti-microbial therapy is usually indicated.
Question 2.c
Are there risk factors for post-LT infections? Organ donors are screened for infectious risks on the basis of national organ-procurement standards (risk of false positive and false negative) (BIII) [35, 36] . Comment: Site-specific colonization study is useful for methicillin resistant Staphylococcus aureus (MRSA), Vancomycin resistant enterococci (VRE), extended-spectrum beta-lactamase (ESBL), and carbapenemase-producing GNB. Other surveillance should be adopted according to the donor and recipient pretransplant data. Microbiological surveillance on biliary fluids is not mandatory [29, 31, 37] . Vancomycin is not utilized due to the increasing risk of VRE selection [27, 31] . Comment: Indication for surgical prophylaxis must be defined according to the local epidemiology [38] . The measurement of efficacy of prophylactic regimens in reducing the rate of post-LT infections is difficult, because no controlled studies have compared prophylaxis with no prophylaxis or the efficacy of antimicrobial prophylactic regimens different from cefotaxime and ampicillin. Indeed, a wide variety of antimicrobial combination regimens are utilized among different centres [38] . Traditional prophylactic regimens in liver transplantation have consisted of a third-generation cephalosporin (usually cefotaxime, because of its antistaphylococcal activity) plus ampicillin to cover enterococci. A reasonable alternative is Piperacillin-tazobactam which covers enterobacteriaceae, enterococci and Pseudomonas. In pre-emptive setting of targeted groups of patients, laboratory monitoring of CMV infection is performed by pp65 antigenemia or NAT at regular weekly or twice a week intervals. Lack of standardization across different laboratories is a problem for both tests and centres need to validate their own threshold values. A safe cut-off determined by real-time PCR was demonstrated to range between 100,000 and 300,000 copies/ml of whole blood according to the type of commercial test used. The suggested cut-offs for pre-emptive therapy have been recently validated and are homogeneously and reliably quantified by different methods (both commercial and in-house) and by different laboratories. It is however recommended that each transplant center should work with their clinical laboratories to define the relevant viral load thresholds for their clinical applications. In 2011, the WHO released the first International Reference Standard for the quantification of CMV nucleic acid, and laboratory and commercially developed CMV QNAT assays should now be calibrated to this standard. This may ensure uniformity in viral load reporting, thereby facilitating to define viral thresholds for various clinical applications. In case of persistently positive CMV-DNA antiviral resistance can be screened in vitro and treatment switch to foscarnet in case of documented resistance is advisable [40] [41] [42] [43] [44] [45] [46] [47] . -''Universal prophylaxis'': D+/RÀ, (3-6 months post-TX): valganciclovir 900 mg/day, oral ganciclovir (3 g/day), or intravenous ganciclovir (5 mg (kg/day) -''Pre-emptive therapy'': the most widely adopted starting criteria for pre-emptive CMV antiviral therapy are [48, 49] :
In CMV seronegative and/or seropositive: DNAemia P100,000 copies/ml In case of Steroid boluses or ATG/OKT3 therapy for Rejection: any value of DNAemia -The drug of choice for treatment is ganciclovir (5 mg/kg bid i.v.). Valganciclovir (900 mg bid oral) is an alternative, although it is not approved for this indication in CMV seropositive recipients [48] [49] [50] (II A) -Pre-emptive treatment should be stopped after two consecutive negative CMV viral load performed during treatment) (II A)
Comment: The optimal duration of intravenous or oral treatment after resolution of clinical signs is uncertain. Serial PCR of CMV DNA offers an objective measure of the degree of viraemia and may help to guide the duration of treatment. In all recipients antiviral therapy must be continued until DNAemia clearance. Recurrent episodes of active infection are usually treated with additional courses of ganciclovir starting with DNAemia values P100,000 copies/ml. Comment: Range of IFI incidence after liver transplantation is reported to be wide (4-42%). According to the most recent data based on strict definitions, the incidence is usually reported to be lower (<10% range 2-8%). Among IFI, the majority are sustained by Candida species (from 68 to 78.7%) followed by Aspergillus species (7.9-11%) and Cryptococcus neoformans (6-7.1%) Timing of IFI ranges from early (<3 months) to late (>6 months) period after liver transplantation [27, [51] [52] [53] [54] [55] [56] . Comment: Targeted antifungal prophylaxis (the use of an antifungal agent in a subgroup of transplanted recipients at higher risk for the presence of predisposing conditions and/or risk factors for Candida and for Candida and Aspergillus) represents the ideal treatment strategy. Different therapeutic strategies are to be considered for the risk of Candida and Aspergillus [10, 27, 51, [57] [58] [59] [60] [61] [62] [63] . Antifungal prophylaxis is suggested only for high-risk patients (fluconazole 400 mg/kg daily or liposomal AmB (L-AmB) 3-5 mg/kg daily up to 4 weeks. or until resolution of symptoms). All of the azole-derivative antifungal agents decrease the metabolism of calcineurin inhibitors and Sirolimus resulting in modest to profound increases in serum concentration and AUC. The interaction of fluconazole with calcineurin inhibitors is both dose-and drug-dependent. At modest doses (100-200 mg/day) of fluconazole used for nonsystemic candidiasis, effects on CsA are minor, while moderate to significant increases are seen with Tacrolimus. At doses of fluconazole required for systemic fungal infection (e.g., 400 mg for cryptococcosis or candidemia), dose reduction of immunosuppressants is required. The new echinocandin antifungal agents provide alternatives to the use of azole derivatives [62, 63, 61] . (Table 4) .
Question 2.q
What is the diagnostic work-up in liver transplant recipients with lower-tract respiratory infections? Statement 2.q -Nasopharyngeal swab for respiratory viruses PCR or antigens, viral PCRs on blood, fungal and acid-fast bacilli (AFB) blood cultures, sputum culture and chest X-ray must be performed (I A) -More sensitive diagnostic tools, i.e., thoracic CT scan, BAL, and thoracentesis in case of pleural effusion should always be considered (III A)
Comment: Leukocytosis, new infiltrate on chest film, and hypoxemia is reported as the typical triad in post-LT lung infections [88] . Various causes, including opportunistic (P. jiroveci, atypical mycobacteria, viruses), rare pathogens (i.e., metapneumovirus, Rhodococcus equi, etc.), and highly resistant germs (MRSA, Pseudomonas, Stenotrophomonas, Bulkholderia, carbapenem-resistant Gram (-)) should be considered. Fever, increased sputum, dyspnoea and/or low oxygen saturation are common [88] . Pneumocystis jiroveci pneumonia (PJP) prophylaxis, according to the international guidelines, is recommended for 6-12 months post-transplant (Tables 5 and 6 ). Efforts to obtain an isolated organism for sensitivity testing should be made (III A) Avoid rifampicin due to difficulty in maintaining adequate levels of immunosuppression and risk of organ rejection (III B) Prolonged treatment (12-18 months) recommended in rifampicin-sparing regimens and extrapulmonary TB (III B) Alternative regimens: isoniazid + ethambutol + pyrazinamide or use of quinolones (moxifloxacin, levofloxacin) (II C) In HIV-infected liver transplant recipient avoidance of rifamycins + addition of a quinolone are recommended (III B) Consultation with a TB specialist is mandatory [89, 90] 
(III A)
Comment: Latent tuberculosis is not a contraindication to liver transplantation but requires pre or post-transplant treatment according to the clinical conditions and the international guidelines.
Both latent (anergy -skin test negativity) and active TB are difficult to diagnose. There is no wide literature-based consensus on TB infection management, and most clinical practice is based upon experts' opinion [91] [92] [93] . It is recommended that the approach to the treatment of TB in solid organ transplant recipients is similar to immunocompetent hosts. However, the following important issues specific to solid organ transplant recipients should be highlighted: (a) rifamycin-containing regimen is strongly preferred for both severe and localized non-severe TB due to the potent sterilizing activity of such regimens and the importance of preventing the emergence of resistance; (b) the rifamycins (especially rifampicin) reduce serum concentrations of tacrolimus, cyclosporine, rapamycin (sirolimus), and everolimus via induction of the cytochrome p450 isoenzyme CYP3A4, and this bears the risk of inducing rejection. Therefore, dose of the CNI or rapamycin should be increased accordingly and serum concentrations regularly monitored.
Question 2.s
What is the management of the most common food-borne diseases in liver transplant recipients? Statement 2.s -Most foodborne diseases are self-limited and require only supportive care while in immunocompromised patients an antibiotics treatment is often required (III B) ( Table 7 ) -Prevention is essential in reducing the cases of foodborne illness. Education of patients and their caregivers is crucial (I B)
Comment: Salmonellosis, listeriosis, and parasitic diseases may cause severe infections in liver transplant recipients [94] [95] [96] . 
Candidiasis and aspergillosis Site of infection Invasive candidiasis
Invasive aspergillosis Empirical treatment if IC suspected*.
• (Table 8) .
Comment: Rates of Nocardiosis in liver transplant recipient varies between 0.7% and 3.5%. Nocardiosis is unlikely earlier than 1 month post-liver transplantation (can exceptionally be seen in cases of extremely high immunosuppression). The infection typically occurs via respiratory entry (i.e., inhalation of contaminated dust) with blood dissemination in 18-40% of cases with granulomatous pulmonary forms and frequently multiple abscesses (cerebral abscesses). The identified risk factors are: high dose steroids, CMV disease, and severe hypogammaglobulinemia. Antimicrobial susceptibility varies with species. Delayed onset of Nocardiosis can be observed because of TMP/SMZ prophylaxis. Cephalosporins and minocycline can be used after initial therapy, however with variable outcomes [102] .
